Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

WIN 2012 /
Use of genetic variance to identify potential therapeutic targets

28th - 29th Jun 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 11.07.12
Views: 3893
Rating:

Dr John Quackenbush - Dana-Farber Cancer Institute, Boston, USA

Dr John Quackenbush talks to ecancertv about a new approach for cancer treatment development. By assessing the differences in gene expression in patients with specific tumour types, it is possible to identify pathways which show very low genetic variance between patients.

Dr Quackenbush explains how this low variance can be used as an indicator to identify pathways that are integral for cancer development and consequently which can be seen as a good target for treatments.

Initial analysis of a large dataset compiled by the Dana-Farber Cancer Institute has confirmed that a large number of known drug targets fit into this pattern.

 

Filming Supported by Amgen

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation